274 related articles for article (PubMed ID: 9667969)
1. Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.
Webber SE; Okano K; Little TL; Reich SH; Xin Y; Fuhrman SA; Matthews DA; Love RA; Hendrickson TF; Patick AK; Meador JW; Ferre RA; Brown EL; Ford CE; Binford SL; Worland ST
J Med Chem; 1998 Jul; 41(15):2786-805. PubMed ID: 9667969
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
Dragovich PS; Prins TJ; Zhou R; Webber SE; Marakovits JT; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Ford CE; Burke BJ; Rejto PA; Hendrickson TF; Tuntland T; Brown EL; Meador JW; Ferre RA; Harr JE; Kosa MB; Worland ST
J Med Chem; 1999 Apr; 42(7):1213-24. PubMed ID: 10197965
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Reich SH; Prins TJ; Marakovits JT; Littlefield ES; Zhou R; Tikhe J; Ford CE; Wallace MB; Meador JW; Ferre RA; Brown EL; Binford SL; Harr JE; DeLisle DM; Worland ST
J Med Chem; 1998 Jul; 41(15):2806-18. PubMed ID: 9667970
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.
Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Reich SH; Marakovits JT; Prins TJ; Zhou R; Tikhe J; Littlefield ES; Bleckman TM; Wallace MB; Little TL; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; DeLisle DM; Worland ST
J Med Chem; 1998 Jul; 41(15):2819-34. PubMed ID: 9667971
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.
Webber SE; Tikhe J; Worland ST; Fuhrman SA; Hendrickson TF; Matthews DA; Love RA; Patick AK; Meador JW; Ferre RA; Brown EL; DeLisle DM; Ford CE; Binford SL
J Med Chem; 1996 Dec; 39(26):5072-82. PubMed ID: 8978838
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication.
Kong JS; Venkatraman S; Furness K; Nimkar S; Shepherd TA; Wang QM; Aubé J; Hanzlik RP
J Med Chem; 1998 Jul; 41(14):2579-87. PubMed ID: 9651162
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.
Dragovich PS; Prins TJ; Zhou R; Fuhrman SA; Patick AK; Matthews DA; Ford CE; Meador JW; Ferre RA; Worland ST
J Med Chem; 1999 Apr; 42(7):1203-12. PubMed ID: 10197964
[TBL] [Abstract][Full Text] [Related]
8. NMR solution structures of the apo and peptide-inhibited human rhinovirus 3C protease (Serotype 14): structural and dynamic comparison.
Bjorndahl TC; Andrew LC; Semenchenko V; Wishart DS
Biochemistry; 2007 Nov; 46(45):12945-58. PubMed ID: 17944485
[TBL] [Abstract][Full Text] [Related]
9. Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation.
Reich SH; Johnson T; Wallace MB; Kephart SE; Fuhrman SA; Worland ST; Matthews DA; Hendrickson TF; Chan F; Meador J; Ferre RA; Brown EL; DeLisle DM; Patick AK; Binford SL; Ford CE
J Med Chem; 2000 May; 43(9):1670-83. PubMed ID: 10794684
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors.
Dragovich PS; Zhou R; Webber SE; Prins TJ; Kwok AK; Okano K; Fuhrman SA; Zalman LS; Maldonado FC; Brown EL; Meador JW; Patick AK; Ford CE; Brothers MA; Binford SL; Matthews DA; Ferre RA; Worland ST
Bioorg Med Chem Lett; 2000 Jan; 10(1):45-8. PubMed ID: 10636240
[TBL] [Abstract][Full Text] [Related]
11. Non-covalent inhibitors of rhinovirus 3C protease.
Baxter A; Chambers M; Edfeldt F; Edman K; Freeman A; Johansson C; King S; Morley A; Petersen J; Rawlins P; Spadola L; Thong B; Van de Poël H; Williams N
Bioorg Med Chem Lett; 2011 Jan; 21(2):777-80. PubMed ID: 21183345
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.
Dragovich PS; Prins TJ; Zhou R; Johnson TO; Hua Y; Luu HT; Sakata SK; Brown EL; Maldonado FC; Tuntland T; Lee CA; Fuhrman SA; Zalman LS; Patick AK; Matthews DA; Wu EY; Guo M; Borer BC; Nayyar NK; Moran T; Chen L; Rejto PA; Rose PW; Guzman MC; Dovalsantos EZ; Lee S; McGee K; Mohajeri M; Liese A; Tao J; Kosa MB; Liu B; Batugo MR; Gleeson JP; Wu ZP; Liu J; Meador JW; Ferre RA
J Med Chem; 2003 Oct; 46(21):4572-85. PubMed ID: 14521419
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.
Namoto K; Sirockin F; Sellner H; Wiesmann C; Villard F; Moreau RJ; Valeur E; Paulding SC; Schleeger S; Schipp K; Loup J; Andrews L; Swale R; Robinson M; Farady CJ
Bioorg Med Chem Lett; 2018 Mar; 28(5):906-909. PubMed ID: 29433930
[TBL] [Abstract][Full Text] [Related]
14. Development of potent inhibitors of the coxsackievirus 3C protease.
Lee ES; Lee WG; Yun SH; Rho SH; Im I; Yang ST; Sellamuthu S; Lee YJ; Kwon SJ; Park OK; Jeon ES; Park WJ; Kim YC
Biochem Biophys Res Commun; 2007 Jun; 358(1):7-11. PubMed ID: 17485072
[TBL] [Abstract][Full Text] [Related]
15. A continuous colorimetric assay for rhinovirus-14 3C protease using peptide p-nitroanilides as substrates.
Wang QM; Johnson RB; Cox GA; Villarreal EC; Loncharich RJ
Anal Biochem; 1997 Oct; 252(2):238-45. PubMed ID: 9344409
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of 3C protease from human rhinovirus strain 1B by peptidyl bromomethylketonehydrazides.
Kati WM; Sham HL; McCall JO; Montgomery DA; Wang GT; Rosenbrook W; Miesbauer L; Buko A; Norbeck DW
Arch Biochem Biophys; 1999 Feb; 362(2):363-75. PubMed ID: 9989947
[TBL] [Abstract][Full Text] [Related]
17. New anti-viral drugs for the treatment of the common cold.
Maugeri C; Alisi MA; Apicella C; Cellai L; Dragone P; Fioravanzo E; Florio S; Furlotti G; Mangano G; Ombrato R; Luisi R; Pompei R; Rincicotti V; Russo V; Vitiello M; Cazzolla N
Bioorg Med Chem; 2008 Mar; 16(6):3091-107. PubMed ID: 18248816
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease.
Johnson TO; Hua Y; Luu HT; Brown EL; Chan F; Chu SS; Dragovich PS; Eastman BW; Ferre RA; Fuhrman SA; Hendrickson TF; Maldonado FC; Matthews DA; Meador JW; Patick AK; Reich SH; Skalitzky DJ; Worland ST; Yang M; Zalman LS
J Med Chem; 2002 May; 45(10):2016-23. PubMed ID: 11985469
[TBL] [Abstract][Full Text] [Related]
19. Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease.
Kawatkar SP; Gagnon M; Hoesch V; Tiong-Yip C; Johnson K; Ek M; Nilsson E; Lister T; Olsson L; Patel J; Yu Q
Bioorg Med Chem Lett; 2016 Jul; 26(14):3248-3252. PubMed ID: 27265257
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.
Dragovich PS; Prins TJ; Zhou R; Johnson TO; Brown EL; Maldonado FC; Fuhrman SA; Zalman LS; Patick AK; Matthews DA; Hou X; Meador JW; Ferre RA; Worland ST
Bioorg Med Chem Lett; 2002 Mar; 12(5):733-8. PubMed ID: 11858991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]